№ files_lp_3_process_7_034707
File format: docx
Character count: 1756
File size: 15 KB
Provides a concise historical and clinical summary of amyotrophic lateral sclerosis, describing its discovery, symptoms, progression, and current approaches to symptom management.
Year of Discovery:
1870s
Location of Discovery:
Paris, France
Medical Field:
Neurology
Document Type:
Informational article
Author:
Samantha Budge
Target Audience:
General public, students of human biology
Affected Population:
Mostly active adults
Symptoms:
Muscle weakness, poor balance, speech and swallowing difficulties, fatigue
Progression:
Loss of mobility, respiratory support needed, dietary adjustments
Life Expectancy:
Typically 2–8 years, occasionally over 10 years
Treatment Approaches:
Medications for spasms and cramps, physical therapy, rest, dietary management
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / Country:
Australia
Drug:
Edaravone (Radicava®)
Type of Document:
Pharmaceutical Benefits Submission
Regulatory Body:
Therapeutic Goods Administration (TGA)
Submission Purpose:
PBS Section 100 Highly Specialised Drugs Listing
Indication:
Amyotrophic lateral sclerosis (ALS)
Treatment Phase:
Initial and Continuing treatment
Prescriber Type:
Medical Practitioners, Nurse Practitioners (continuing therapy only)
Clinical Criteria:
Diagnosis by neurologist, disease duration ≤ 2 years, FVC or SVC ≥ 80% predicted, ambulatory or upper limb/swallowing ability, ALSFRS-R ≥ 2 on each item, no tracheostomy or respiratory failure
Population:
Adult patients (≥18 years)
Pricing:
Special Pricing Arrangements apply
Regulatory Dates:
Orphan designation 17 August 2021, TGA registration 15 February 2023
Comparator:
Standard of care with or without riluzole
Outcomes Measured:
ALS Functional Rating Scale – Revised (ALSFRS-R) after 6 months
Year:
2025
Region / City:
United Kingdom
Topic:
COVID-19 treatment, lateral flow device tests
Document Type:
Service Specification
Organization / Institution:
NHS England
Author:
NHS England
Target Audience:
Pharmacy contractors, healthcare professionals
Period of Validity:
Ongoing, from 6 November 2023
Date of Approval:
May 2025
Date of Changes:
01 May 2025
Year:
2023
Region / Country:
Australia
Drug:
Edaravone (Radicava®)
Type of Document:
Pharmaceutical Benefits Submission
Regulatory Body:
Therapeutic Goods Administration (TGA)
Submission Purpose:
PBS Section 100 Highly Specialised Drugs Listing
Indication:
Amyotrophic lateral sclerosis (ALS)
Treatment Phase:
Initial and Continuing treatment
Prescriber Type:
Medical Practitioners, Nurse Practitioners (continuing therapy only)
Clinical Criteria:
Diagnosis by neurologist, disease duration ≤ 2 years, FVC or SVC ≥ 80% predicted, ambulatory or upper limb/swallowing ability, ALSFRS-R ≥ 2 on each item, no tracheostomy or respiratory failure
Population:
Adult patients (≥18 years)
Pricing:
Special Pricing Arrangements apply
Regulatory Dates:
Orphan designation 17 August 2021, TGA registration 15 February 2023
Comparator:
Standard of care with or without riluzole
Outcomes Measured:
ALS Functional Rating Scale – Revised (ALSFRS-R) after 6 months
Year:
2023
Note:
Region/City
Topic:
Legal Recruitment
Document Type:
Questionnaire
Organization/Institution:
NALSC®
Author:
NALSC®
Target Audience:
Legal professionals, law firms, recruiters
Year:
Not specified
Region / City:
Not specified
Topic:
Military application
Document Type:
Instructions
Organization / Institution:
Australian Defence Force
Author:
Not specified
Target Audience:
Applicants to the Australian Defence Force
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
Manado
Topic:
Medical Rehabilitation
Document Type:
Case Report
Institution:
RSUP Kandou Manado
Author:
Natalia Nanlohy, Joudy Gessal, Christina Adelle Damopolii
Target Audience:
Medical professionals, researchers
Duration:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2018-2021
Note:
Region / City
Subject:
Master of Computer Applications Program Structure
Document Type:
Academic Program
Institution:
School of Engineering
Target Audience:
Students of MCA Program
Period of Validity:
2018-2021
Year:
2021
Region / City:
Zhejiang Province, China
Topic:
Epilepsy, Neuroscience
Document Type:
Research Article
Organization / Institution:
Zhejiang University
Author:
Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience:
Researchers in neuroscience and epilepsy
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Utsunomiya, Japan
Subject:
Digital Holography, Industrial Measurement
Document Type:
Research Paper
Institution:
Utsunomiya University, Center for Optical Research and Education (CORE)
Author:
Yuma Sato, Yoshio Hayasaki
Target Audience:
Researchers, Engineers in Optical Measurement
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019
Region / City:
Not specified
Topic:
Patient-reported outcome measures in hip disorders
Document Type:
Systematic review
Author:
Beck et al.
Target Audience:
Healthcare professionals, researchers in orthopedics
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Condition:
Tennis Elbow (Lateral Elbow Tendinopathy)
Alternative names:
Lateral epicondylitis
Type of document:
Patient information leaflet
Medical field:
Musculoskeletal health
Affected area:
Elbow and forearm
Common age range:
40–60 years
Prevalence:
Up to 1 in 3 people during lifetime
Primary symptoms:
Lateral elbow pain radiating to forearm and wrist
Common causes:
Repetitive wrist extension, gripping and forearm overuse
Diagnostic method:
Clinical assessment and physical examination
Imaging:
Ultrasound or other imaging if nerve damage suspected
Conservative management:
Activity modification, exercise therapy, ice application, support strap, analgesia
Recovery duration:
6 months to 2 years
Rehabilitation response time:
Up to 12 weeks
Referral options:
Physiotherapy, shockwave therapy, steroid injection, surgery
Lifestyle considerations:
Stress management, sleep, alcohol avoidance, smoking cessation, physical activity
Target audience:
Patients experiencing lateral elbow pain
Year:
2024
Country:
Nigeria
State:
Nasarawa State
City / Area:
Keffi
Institution:
Federal Medical Centre Keffi
Department:
Medical Laboratory Department, Blood Bank
Document Type:
Original Research Article
Study Design:
Cross-sectional study
Study Period:
March 2024 – September 2024
Sample Size:
240 blood donors
Population:
Blood donors aged 18–65 years meeting eligibility criteria
Research Focus:
Viral transfusion-transmissible infections (HIV, HBV, HCV)
Diagnostic Methods:
Rapid Diagnostic Test (RDT), Enzyme-Linked Immunosorbent Assay (ELISA)
Primary Outcome:
Seroprevalence of transfusion-transmissible viral infections among blood donors
Keywords:
Blood Donors, Enzyme-linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test (RDT), Transfusion-Transmissible Infections (TTIs), Nasarawa
Year:
2021
Institution:
University of Washington
Department:
University of Washington Police Department (UWPD)
City:
Seattle
State:
Washington
Country:
United States
Document type:
Job vacancy announcement
Position title:
Campus Police Officer (Lateral)
Posting date:
February 4, 2021
Closing date:
March 7, 2021
Work location:
Seattle Campus
Salary range:
$5,799–$7,611 per month
Union position:
Yes
Work shift:
First shift (varies by assignment)
Number of openings:
Multiple openings
Employment category:
Law enforcement personnel
Selection process:
Oral board interview, writing exam, ride-along, background investigation, polygraph, medical and psychological examination
Jurisdiction:
University of Washington main campus and surrounding areas
Accreditation references:
CALEA, IACLEA, Washington Association of Sheriffs & Police Chiefs
Year:
Not provided
Region / City:
Not provided
Topic:
Statistical analysis, segmentation, CBCT, MRI, cephalometry
Document Type:
Research article
Organization / Institution:
Not provided
Author:
Abkai et al, Juerchott et al, Jency et al, Grandoch et al, Maspero et al, Heil et al, Eley et al, Tai et al
Target Audience:
Researchers, clinicians, medical imaging specialists
Period of validity:
Not provided
Approval Date:
Not provided
Date of Changes:
Not provided
Context:
Research article evaluating the level of agreement between different imaging modalities (CBCT, MRI, cephalogram) using various statistical methods.
Year:
2026
Region / City:
Not specified
Subject:
Education, Diploma bridging programmes
Document Type:
Annexure
Institution:
Not specified
Target Audience:
Diploma holders seeking lateral entry
Programme Duration:
Not specified
Number of Modules:
Not specified
Module Codes:
Provided
Module Names:
Provided
Contact Hours:
Provided
Non-Contact Hours:
Provided
Note:
Year
Document type:
Shared Care Guideline
Organization / Institution:
North Central London Joint Formulary Committee
Target Audience:
Primary Care Prescribers
Year:
2023
Region / Country:
Australia
Drug:
Edaravone (Radicava®)
Type of Document:
Pharmaceutical Benefits Submission
Regulatory Body:
Therapeutic Goods Administration (TGA)
Submission Purpose:
PBS Section 100 Highly Specialised Drugs Listing
Indication:
Amyotrophic lateral sclerosis (ALS)
Treatment Phase:
Initial and Continuing treatment
Prescriber Type:
Medical Practitioners, Nurse Practitioners (continuing therapy only)
Clinical Criteria:
Diagnosis by neurologist, disease duration ≤ 2 years, FVC or SVC ≥ 80% predicted, ambulatory or upper limb/swallowing ability, ALSFRS-R ≥ 2 on each item, no tracheostomy or respiratory failure
Population:
Adult patients (≥18 years)
Pricing:
Special Pricing Arrangements apply
Regulatory Dates:
Orphan designation 17 August 2021, TGA registration 15 February 2023
Comparator:
Standard of care with or without riluzole
Outcomes Measured:
ALS Functional Rating Scale – Revised (ALSFRS-R) after 6 months
Year:
2019
Region / City:
South East London
Subject:
Shared care prescribing guidelines for spasticity treatment
Document type:
Clinical guideline
Author:
Not specified
Target audience:
General Practitioners (GPs), specialists, healthcare providers
Period of validity:
Ongoing
Approval date:
Not specified
Date of modifications:
Not specified
Year:
2023
Region / city:
UK
Theme:
Respiratory issues, multiple sclerosis (MS), physiotherapy
Document type:
Guidance
Organization / institution:
MS Trust
Author:
Jody Barber, Michelle Davies, Michelle Koch, Wendy Hendrie, Rhian O’Halloran, Ruth O’Regan
Target audience:
Physiotherapists, healthcare professionals
Action period:
Ongoing
Approval date:
March 2023
Revision date:
None mentioned